Fate Therapeutics reports positive FT516 and FT596 Phase 1 data; FT516 gets RMAT designation for DLBCL

FATE THERAPEUTICS INC

FT516: 6 of 10 CAR T-naive patients in ongoing response at median 9.1 months; 3 of 8 prior CAR T patients achieve CR.
FDA granted RMAT designation for FT516 in relapsed/refractory DLBCL; dose expansion at 900M cells/dose initiated.
FT596: 5 of 6 patients achieve objective response (4 CR) with single dose at 900M cells in combination with rituximab.
FT596: 10 of 11 patients treated with second cycle continue in ongoing response; 3 in CR ≥6 months. No ICANS or GvHD observed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.